{"id":607823,"date":"2022-07-12T20:20:01","date_gmt":"2022-07-12T20:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=607823"},"modified":"2022-07-12T20:20:01","modified_gmt":"2022-07-12T20:20:01","slug":"fibrodysplasia-ossificans-progressiva-fop-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-ipsen","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fibrodysplasia-ossificans-progressiva-fop-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-ipsen_607823.html","title":{"rendered":"Fibrodysplasia ossificans progressiva (FOP) Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies &#8211; Ipsen,"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1657617467.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Fibrodysplasia ossificans progressiva (FOP) Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies - Ipsen,\" src=\"https:\/\/www.abnewswire.com\/uploads\/1657617467.jpeg\" alt=\"Fibrodysplasia ossificans progressiva (FOP) Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies - Ipsen,\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cFibrodysplasia ossificans progressiva (FOP) &#8211; Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Fibrodysplasia ossificans progressiva (FOP), historical and forecasted epidemiology as well as the Fibrodysplasia ossificans progressiva (FOP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/fibrodysplasia-ossificans-progressiva-fop-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Fibrodysplasia ossificans progressiva (FOP) Market<\/a> Insights, Epidemiology, and Market Forecast-2032&rdquo;.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;Fibrodysplasia ossificans progressiva (FOP) &#8211; Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an in-depth understanding of the Fibrodysplasia ossificans progressiva (FOP), historical and forecasted epidemiology as well as the Fibrodysplasia ossificans progressiva (FOP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Some of the key facts of the Fibrodysplasia ossificans progressiva (FOP) Market Report:<\/p>\n<ul style=\"text-align: justify;\">\n<li>According to a study by Moira et al. (2021), the prevalence of FOP is approximately 0.65 per million in North America&nbsp;<\/li>\n<li>According to the European Conference on Rare Diseases, FOP has a prevalence rate of 0.08 per 100,000 people&nbsp;<\/li>\n<li>According to a study by Robert J et al. (2021), most individuals living with FOP (87%) were alive in the first five decades (0-49 years of age) of their lives&nbsp;<\/li>\n<li>According to Robert et al. (2021), an estimated minimum prevalence is 0.88 per million individuals (1 in 1.14 million people) in the United States&nbsp;<\/li>\n<li>As per the data collected from various studies, the prevalence of FOP is more in females than in males&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Request a sample for the Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-market<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Key benefits of the report:<\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Fibrodysplasia ossificans progressiva (FOP) market report covers a descriptive overview and comprehensive insight of the Fibrodysplasia ossificans progressiva (FOP) Epidemiology and Fibrodysplasia ossificans progressiva (FOP)&nbsp; market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Fibrodysplasia ossificans progressiva (FOP) market report provides insights on the current and emerging therapies.<\/li>\n<li>Fibrodysplasia ossificans progressiva (FOP) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Fibrodysplasia ossificans progressiva (FOP) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fibrodysplasia ossificans progressiva (FOP) market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Epidemiology Segmentation:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalent cases of Fibrodysplasia Ossificans Progressiva in the 7MM [2019&ndash;2032]<\/li>\n<li>Total Diagnosed Prevalent cases of Fibrodysplasia Ossificans Progressiva in the 7MM [2019&ndash;2032]<\/li>\n<li>Gender-specific cases of Fibrodysplasia Ossificans Progressiva [2019&ndash;2032]<\/li>\n<li>Age-specific cases of Fibrodysplasia Ossificans Progressiva [2019&ndash;2032]<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Got queries? Click here to know more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Fibrodysplasia ossificans progressiva (FOP) Market Landscape<\/a>&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Fibrodysplasia ossificans progressiva (FOP) Overview:&nbsp;<\/p>\n<p style=\"text-align: justify;\">Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body&rsquo;s skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible.&nbsp;<\/p>\n<p style=\"text-align: justify;\">FOP is caused by a mutation in the ACVR1 gene. This gene is involved in growth and development of bones. The mutation allows them to grow unchecked. The gene can be inherited from one parent, but in most cases of FOP, it&#8217;s a new mutation in a person with no family history of the disease.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Fibrodysplasia ossificans progressiva (FOP) Symptoms:<\/p>\n<p style=\"text-align: justify;\">The symptoms of Fibrodysplasia ossificans progressiva include &ndash;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Repeated episodes of muscle swelling and inflammation<\/li>\n<li>Difficulty in speaking and eating<\/li>\n<li>Malformed big toes<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Fibrodysplasia ossificans progressiva (FOP) Market &nbsp;<\/p>\n<p style=\"text-align: justify;\">The dynamics of the Fibrodysplasia ossificans progressiva (FOP) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as IPN60130, Garetosmab, and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Learn more by requesting for sample @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Fibrodysplasia ossificans progressiva (FOP) Market Landscape<\/a> &nbsp;<\/p>\n<p style=\"text-align: justify;\">Fibrodysplasia ossificans progressiva (FOP) Pipeline Therapies:<\/p>\n<ul style=\"text-align: justify;\">\n<li>IPN60130<\/li>\n<li>Garetosmab<\/li>\n<li>Palovarotene<\/li>\n<li>REGN2477&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Fibrodysplasia ossificans progressiva (FOP) Pipeline Key Companies:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Ipsen<\/li>\n<li>Incyte Corporation<\/li>\n<li>&nbsp;Regeneron Pharmaceuticals<\/li>\n<li>Clementia Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Table of Contents&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. Fibrodysplasia ossificans progressiva (FOP) Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Fibrodysplasia ossificans progressiva (FOP) Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Fibrodysplasia ossificans progressiva (FOP) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Fibrodysplasia ossificans progressiva (FOP) Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Fibrodysplasia ossificans progressiva (FOP) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Fibrodysplasia ossificans progressiva (FOP)&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Fibrodysplasia ossificans progressiva (FOP) Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Fibrodysplasia ossificans progressiva (FOP) Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Fibrodysplasia ossificans progressiva (FOP) Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Fibrodysplasia ossificans progressiva (FOP) Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Fibrodysplasia ossificans progressiva (FOP) Market Analysis (2018&ndash;2030)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Fibrodysplasia ossificans progressiva (FOP) Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Click here to read more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Fibrodysplasia ossificans progressiva (FOP) Market Outlook 2032<\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=fibrodysplasia-ossificans-progressiva-fop-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-ipsen\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91 9568243403<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=fibrodysplasia-ossificans-progressiva-fop-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-ipsen\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cFibrodysplasia ossificans progressiva (FOP) &#8211; Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Fibrodysplasia ossificans progressiva (FOP), historical and forecasted epidemiology as well as the Fibrodysplasia ossificans progressiva (FOP) market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/fibrodysplasia-ossificans-progressiva-fop-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-ipsen_607823.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[447,405,417,406,423],"tags":[],"class_list":["post-607823","post","type-post","status-publish","format-standard","hentry","category-Education","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/607823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=607823"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/607823\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=607823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=607823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=607823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}